{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-003554","form_type":"8-K","ticker":"ALNY","cik":"0001178670","company_name":"ALNYLAM PHARMACEUTICALS, INC.","filed_at":"2023-01-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:44.062611+00:00","generated_at":"2026-06-20T18:37:06.651746+00:00","sec_items":["5.02","8.01","9.01"],"event_type":"leadership","sentiment":"positive","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"Alnylam appoints Nobel laureate Carolyn Bertozzi to board; Amy Schulman becomes Chair","bullets":["Carolyn Bertozzi, Ph.D., Nobel laureate in chemistry, elected to Board effective Jan. 5, 2023.","Bertozzi receives $55,000 annual cash retainer and option for 4,268 shares at $225.68.","Michael W. Bonney steps down as Executive Chair, continues as non-independent director.","Lead Independent Director Amy W. Schulman appointed Chair of the Board.","Board expands from 11 to 12 directors; Bertozzi to serve as Class III director until 2025 annual meeting."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-003554","json":"https://secwatch.observer/filing/0001193125-23-003554.json","markdown":"https://secwatch.observer/filing/0001193125-23-003554.md","text":"https://secwatch.observer/filing/0001193125-23-003554.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1178670/000119312523003554/0001193125-23-003554-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1178670/000119312523003554/d426017d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T18:37:06.651746+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"5bb87b8502","claim":"Carolyn R. Bertozzi was elected as Director at ALNYLAM PHARMACEUTICALS, INC..","evidence_excerpt":"Effective as of January 5, 2023, the Board of Directors (the “Board”) of Alnylam Pharmaceuticals, Inc. (the “Company”), following the recommendation of its Nominating and Corporate Governance Committee, expanded the size of the Company’s Board from eleven to twelve and elected Dr. Carolyn R. Bertozzi to fill the newly created vacancy.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1178670/000119312523003554/0001193125-23-003554-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"elected"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}